ERBB2 and breast cancer: Second, increased SHP2 phosphorylation is observed in breast cancer cells resistant to the HER2 TKI neratinib, where it acts as a shared signaling node that integrates inputs from the extracellular matrix and receptor tyrosine kinases (RTKs), thereby promoting drug resistance and metastasis (Chen et al., 2020).